- Report
- October 2024
- 198 Pages
Global
From €3360EUR$3,545USD£2,807GBP
€3733EUR$3,939USD£3,119GBP
- Report
- October 2024
- 199 Pages
Global
From €3360EUR$3,545USD£2,807GBP
€3733EUR$3,939USD£3,119GBP
- Report
- April 2025
- 250 Pages
Global
From €5166EUR$5,450USD£4,316GBP
- Report
- April 2025
- 212 Pages
Global
From €5308EUR$5,600USD£4,434GBP
- Report
- May 2024
- 132 Pages
Global
From €6160EUR$6,499USD£5,146GBP
- Report
- May 2024
- 134 Pages
Global
From €6160EUR$6,499USD£5,146GBP
- Report
- May 2024
- 138 Pages
Global
From €6160EUR$6,499USD£5,146GBP
- Report
- May 2024
- 138 Pages
Global
From €6160EUR$6,499USD£5,146GBP
- Report
- August 2024
- 150 Pages
Global
From €2643EUR$2,789USD£2,208GBP
- Report
- August 2024
- 150 Pages
Global
From €2643EUR$2,789USD£2,208GBP
- Report
- November 2023
- 175 Pages
Global
From €4739EUR$5,000USD£3,959GBP
- Report
- June 2023
- 180 Pages
Global
From €5640EUR$5,950USD£4,711GBP
- Report
- March 2024
- 150 Pages
Global
From €4218EUR$4,450USD£3,524GBP
- Report
- March 2024
- 150 Pages
Global
From €4218EUR$4,450USD£3,524GBP
- Report
- December 2023
- 150 Pages
Global
From €4218EUR$4,450USD£3,524GBP
- Drug Pipelines
- February 2024
- 180 Pages
Global
From €2843EUR$3,000USD£2,376GBP
- Report
- November 2023
- 224 Pages
Global
From €7109EUR$7,500USD£5,939GBP
- Report
- February 2023
- 30 Pages
Global
From €2606EUR$2,750USD£2,178GBP
- Report
- November 2023
- 353 Pages
Global
From €9004EUR$9,500USD£7,522GBP
- Drug Pipelines
- January 2023
- 30 Pages
United States
From €2606EUR$2,750USD£2,178GBP

Olaparib is a type of breast cancer drug used to treat advanced breast cancer in women with certain genetic mutations. It is a poly ADP-ribose polymerase (PARP) inhibitor, which works by blocking the action of an enzyme that helps cancer cells repair themselves. This makes it harder for the cancer cells to survive and grow. Olaparib is used in combination with other treatments, such as chemotherapy, to help slow the growth of cancer cells. It is also used to treat metastatic breast cancer, which is cancer that has spread to other parts of the body.
Olaparib is approved by the US Food and Drug Administration (FDA) for the treatment of advanced breast cancer in women with certain genetic mutations. It is also approved in the European Union and other countries.
Some companies in the Olaparib market include AstraZeneca, Merck, Pfizer, and GlaxoSmithKline. These companies are involved in the research, development, and marketing of Olaparib and other breast cancer drugs. Show Less Read more